| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2026―May―25 |
Global Pharmacovigilance: Data for 2017-2025 with an Assessment of the Impact of the COVID-19 Pandemic |
B. K. Romanov, E. Yu. Baidikova, D. A. Kozlov, U. M. Shirokova, E. D. Shchukin |
| 2 |
[GO] |
2025―Jun―25 |
Thrombocytopenia as a Side Effect of Heparin Therapy and COVID-19 Vaccination: A Review |
S. S. Postnikov, N. V. Teplova, O. V. Gulbekova |
| 3 |
[GO] |
2024―May―03 |
Analysis of the Consumption of Medicinal Products Associated with a High Risk of Drug-Induced Liver Injury in Patients with COVID-19 |
V. I. Petrov, A. Yu. Ryazanova, N. S. Tokareva |
| 4 |
[GO] |
2024―Feb―01 |
Quantitative Signal Detection for COVID-19 Medicinal Products Based on Retrospective Analysis of Spontaneous Reports from the Russian Pharmacovigilance Database |
S. A. Mishinova, A. S. Kolbin, Yu. S. Polushin, E. V. Verbickaya |
| 5 |
[GO] |
2023―Sep―11 |
A Case of Diabetes Mellitus after COVID-19 Vaccination in a Patient with Impaired Glucose Metabolism |
I. V. Maiborodin, V. I. Maiborodina, M. G. Klinnikova, E. L. Lushnikova |
| 6 |
[GO] |
2022―Dec―30 |
Structure of Adverse Events Following Immunisation against Coronavirus Infection (COVID-19) in the Kyrgyz Republic |
A. A. Zurdinova, Zh. O. Zhumagulova, A. T. Sharaeva, N. Sultanalieva |
| 7 |
[GO] |
2022―Dec―30 |
Safety of Pharmacotherapy in COVID-19 Patients: A Literature Review |
A. V. Kryukov, A. S. Zhiryakova, Yu. V. Shevchuk, A. V. Matveev, V. I. Vechorko, O. V. Averkov, S. V. Glagolev, I. I. Temirbulatov, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, D. A. Sychev |
| 8 |
[GO] |
2022―Dec―30 |
Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19? |
Article Editorial |
| 9 |
[GO] |
2022―Dec―30 |
Experience of Using Remdesivir in Patients with Novel Coronavirus Infection |
V. I. Petrov, A. Yu. Ryazanova, N. S. Privaltseva, D. A. Nekrasov |
| 10 |
[GO] |
2022―Dec―30 |
Vladimir Chulanov: “Our experience with overcoming the pandemic will help us effectively address future threats” |
Article Editorial |
| 11 |
[GO] |
2022―Oct―31 |
Safety of COVID-19 Vaccines |
B. K. Romanov |
| 12 |
[GO] |
2022―Oct―06 |
Approaches to Assessing the Safety of Medicines during the COVID-19 Pandemic Using the Example of Azithromycin |
Yu. M. Gomon, A. R. Kasimova, A. S. Kolbin, V. V. Strizheletsky, I. G. Ivanov, S. O. Mazurenko |
| 13 |
[GO] |
2022―Jul―19 |
Evaluation of the Rationality of Antibiotic Therapy of Nosocomial Infections in Resuscitation and Intensive Care Patients with COVID-19: a Retrospective Analysis |
K. I. Karnoukh, N. B. Lazareva |
| 14 |
[GO] |
2022―Jul―04 |
Antibiotics for the treatment of COVID-19 |
Article Editorial |
| 15 |
[GO] |
2022―Apr―11 |
Ivermectin: Evaluation of Efficacy and Safety in COVID-19 |
E. V. Shubnikova, N. A. Susekova, T. M. Bukatina, M. S. Galenko, A. A. Druzhinina |
| 16 |
[GO] |
2022―Apr―11 |
Changes in Post-COVID Syndrome Manifestations and Bulbar Conjunctival Angioscopy Results in a Patient Undergoing Treatment after Mild COVID-19 |
V. V. Arkhipov, T. S. Kheilo, E. G. Gladysheva, Yu. A. Danilogorskaya, M. R. Dzhavatkhanova, S. V. Snytko, I. V. Samorukova, M. V. Zhuravleva |
| 17 |
[GO] |
2021―Dec―21 |
Experience in Using Antiviral Agents for the Treatment of Novel Coronavirus Infection (COVID-19) in Kyrgyzstan |
A. A. Zurdinova, A. Z. Kutmanova |
| 18 |
[GO] |
2020―Sep―18 |
Safety of Remdesivir and Tocilizumab in COVID-19 Treatment |
Article Editorial |
| 19 |
[GO] |
2020―Mar―28 |
Coronavirus disease COVID-2019 |
B. K. Romanov |
